Patent ID: 8263627

Claim:
A method for the treatment of schizophrenia which comprises administering to a human patient in need of such treatment an effective amount of a compound of the formula: wherein: R 1a is selected from the group consisting of: (1) halogen, (2) phenyl, which is unsubstituted or substituted with halogen, hydroxyl, C 1-6 alkyl, —O—C 1-6 alkyl, C 3-6 cycloalkyl, or —NO 2 , (3) —O—phenyl, which is unsubstituted or substituted with halogen, hydroxyl, C 1-6 alkyl or —O—C 1-6 alkyl, (4) C 1-6 alkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl, (5) C 3-6 cycloalkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl, and (6) C 2-4 alkenyl, which is unsubstituted or substituted with C 3-6 cycloalkyl or phenyl; R 5a is independently selected from the group consisting of: (1) hydrogen, (2) fluoro, (3) chloro, (4) bromo, (5) hydroxyl, (6) —CH 3 , (7) —CH 2 OH, (8) —CH 2 CH 3 , (9) —CH 2 ═CH 2 , (10) —CH 2 CH 2 CH 3 , (11) -cyclopropyl, (12) —OCH 3 , (13) —OCH 2 F, (14) —OCH 2 -cyclopropyl, (15) —OCH 2 -phenyl, (16) —OCH 2 CH 3 , (17) —OCH 2 CF 3 , (18) —OCH 2 CH 2 CH 3 , (19) —OCH 2 (C═O)OCH 2 CH 3 , (20) —OCH 2 (C═O)NHCH 2 CH 3 , (21) —OSO 2 CH 3 , and (22) —O(C═O)OCH 3 ; or a pharmaceutically acceptable salt thereof.